Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | USP2 | O75604 | 3/20 | 0.35 |
| ▸ | INMT | O95050 | 1/20 | 0.35 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111613 | 1.00 | ALDH1A1 (0.35) | ALDH1A1MAPTUSP2INMTPSMB1 | |
| SCHEMBL8992014 | 1.00 | ALDH1A1 (0.35) | ALDH1A1MAPTUSP2INMTPSMB1 | |
| SCHEMBL497507 | 1.00 | ALDH1A1 (0.35) | ALDH1A1MAPTUSP2INMTPSMB1 | |
| SCHEMBL8992009 | 1.00 | ALDH1A1 (0.35) | ALDH1A1MAPTUSP2INMTPSMB1 | |
| SCHEMBL23486255 | 1.00 | ALDH1A1 (0.35) | ALDH1A1MAPTUSP2INMTPSMB1 | |
| SCHEMBL23661069 | 1.00 | ALDH1A1 (0.35) | ALDH1A1MAPTUSP2INMTPSMB1 | |
| SCHEMBL6699994 | 1.00 | ALDH1A1 (0.35) | ALDH1A1MAPTUSP2INMTPSMB1 | |
| SCHEMBL11110396 | 1.00 | ALDH1A1 (0.35) | ALDH1A1MAPTUSP2INMTPSMB1 | |
| SCHEMBL14818806 | 1.00 | ALDH1A1 (0.35) | ALDH1A1MAPTUSP2INMTPSMB1 | |
| SCHEMBL11082560 | 1.00 | ALDH1A1 (0.35) | ALDH1A1MAPTUSP2INMTPSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024879-A1 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | TWINCORE ZENTRUM FUR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH (DE) | 2022-01-27 | — | — | US | claimed |
| EP-3898593-A2 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | Gottfried Wilhelm Leibniz Universität Hannover (DE) | 2021-10-27 | — | — | EP | claimed |
| WO-2020127211-A2 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | GOTTFRIED WILHELM LEIBNIZ UNIVERSITÄT HANNOVER (DE) | 2020-06-25 | — | — | WO | claimed |
| EP-3670498-A1 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | Gottfried Wilhelm Leibniz Universität Hannover (DE) | 2020-06-24 | — | — | EP | claimed |
| US-20220024879-A1 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | TWINCORE ZENTRUM FUR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH (DE) | 2022-01-27 | — | — | US | disclosed |
| US-20220024879-A1 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | TWINCORE ZENTRUM FUR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH (DE) | 2022-01-27 | — | — | US | disclosed |
| EP-3898593-A2 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | Gottfried Wilhelm Leibniz Universität Hannover (DE) | 2021-10-27 | — | — | EP | disclosed |
| EP-3898593-A2 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | Gottfried Wilhelm Leibniz Universität Hannover (DE) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020127211-A3 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | GOTTFRIED WILHELM LEIBNIZ UNIVERSITÄT HANNOVER (DE) | 2020-07-30 | — | — | WO | disclosed |
| WO-2020127211-A2 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | GOTTFRIED WILHELM LEIBNIZ UNIVERSITÄT HANNOVER (DE) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127211-A2 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | GOTTFRIED WILHELM LEIBNIZ UNIVERSITÄT HANNOVER (DE) | 2020-06-25 | — | — | WO | disclosed |
| EP-3670498-A1 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | Gottfried Wilhelm Leibniz Universität Hannover (DE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3670498-A1 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | Gottfried Wilhelm Leibniz Universität Hannover (DE) | 2020-06-24 | — | — | EP | disclosed |
| US-5932593-A | ANTISEROTONIN AGENT | AJINOMOTO CO., LTD. (JP) | 1999-08-03 | — | — | US | disclosed |
| EP-0157399-B1 | 4-(5H-Dibenzo[a,d]cyclohepten-5-yl) piperidine compounds | MERCK & CO. INC. (US) | 1989-08-16 | — | — | EP | disclosed |
| US-4758577-A | 4-(5H-dibenzo[a,d]cyclohepten-5-yl)piperidine compounds for treating cardiovascular disorders | MERCK & CO., INC. (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0157399-A2 | 4-(5H-Dibenzo[a,d]cyclohepten-5-yl) piperidine compounds | MERCK & CO. INC. (US) | 1985-10-09 | — | — | EP | disclosed |
| US-4221800-A | ANTIALLERGENS, ANTIHISTAMINES | MILES LABORATORIES, INC. (US) | 1980-09-09 | — | — | US | disclosed |
| US-3991111-A | ANTIBIOTICS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-11-09 | — | — | US | disclosed |
| US-3951962-A | ANTIBACTERIAL | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024879-A1 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | HAVCR2, HCCS, HELZ | ALDH1A1 701/4885MAPT 2965/4885USP2 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.